Login to Your Account



Pharma: Other News To Note


Wednesday, January 16, 2013
• Eli Lilly and Co., of Indianapolis, and subsidiary Avid Radiopharmaceuticals Inc. said Amyvid (florbetapir F 18 injection) was approved in Europe as a diagnostic radiopharmaceutical indicated for positron emission tomography imaging of beta-amyloid neuritic plaque density in the brains of adults with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive impairment.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription